Literature DB >> 27987249

Achondroplasia: Development, pathogenesis, and therapy.

David M Ornitz1, Laurence Legeai-Mallet2.   

Abstract

Autosomal dominant mutations in fibroblast growth factor receptor 3 (FGFR3) cause achondroplasia (Ach), the most common form of dwarfism in humans, and related chondrodysplasia syndromes that include hypochondroplasia (Hch), severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN), and thanatophoric dysplasia (TD). FGFR3 is expressed in chondrocytes and mature osteoblasts where it functions to regulate bone growth. Analysis of the mutations in FGFR3 revealed increased signaling through a combination of mechanisms that include stabilization of the receptor, enhanced dimerization, and enhanced tyrosine kinase activity. Paradoxically, increased FGFR3 signaling profoundly suppresses proliferation and maturation of growth plate chondrocytes resulting in decreased growth plate size, reduced trabecular bone volume, and resulting decreased bone elongation. In this review, we discuss the molecular mechanisms that regulate growth plate chondrocytes, the pathogenesis of Ach, and therapeutic approaches that are being evaluated to improve endochondral bone growth in people with Ach and related conditions. Developmental Dynamics 246:291-309, 2017.
© 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  FGF; FGFR3; achondroplasia; chondrogenesis; endochondral ossification; fibroblast growth factor receptor; growth plate; hypochondroplasia; skeletal dysplasia; thanatophoric dysplasia; therapy

Mesh:

Substances:

Year:  2017        PMID: 27987249      PMCID: PMC5354942          DOI: 10.1002/dvdy.24479

Source DB:  PubMed          Journal:  Dev Dyn        ISSN: 1058-8388            Impact factor:   3.780


  239 in total

Review 1.  FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease.

Authors:  David M Ornitz; Pierre J Marie
Journal:  Genes Dev       Date:  2002-06-15       Impact factor: 11.361

Review 2.  Regulation of Long Bone Growth in Vertebrates; It Is Time to Catch Up.

Authors:  Alberto Roselló-Díez; Alexandra L Joyner
Journal:  Endocr Rev       Date:  2015-10-20       Impact factor: 19.871

3.  Bilateral double level tibial lengthening in dwarfism.

Authors:  Rolf D Burghardt; Koichi Yoshino; Naoya Kashiwagi; Shigeo Yoshino; Anil Bhave; Dror Paley; John E Herzenberg
Journal:  J Orthop       Date:  2015-06-03

4.  Disruption of the fibroblast growth factor-2 gene results in decreased bone mass and bone formation.

Authors:  A Montero; Y Okada; M Tomita; M Ito; H Tsurukami; T Nakamura; T Doetschman; J D Coffin; M M Hurley
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

5.  BDNF alters ERK/p38 MAPK activity ratios to promote differentiation in growth plate chondrocytes.

Authors:  Michele R Hutchison
Journal:  Mol Endocrinol       Date:  2012-06-14

Review 6.  The molecular and genetic basis of fibroblast growth factor receptor 3 disorders: the achondroplasia family of skeletal dysplasias, Muenke craniosynostosis, and Crouzon syndrome with acanthosis nigricans.

Authors:  Z Vajo; C A Francomano; D J Wilkin
Journal:  Endocr Rev       Date:  2000-02       Impact factor: 19.871

7.  A neonatal lethal mutation in FGFR3 uncouples proliferation and differentiation of growth plate chondrocytes in embryos.

Authors:  T Iwata; L Chen; C Li; D A Ovchinnikov; R R Behringer; C A Francomano; C X Deng
Journal:  Hum Mol Genet       Date:  2000-07-01       Impact factor: 6.150

8.  Deletion of FGFR3 in Osteoclast Lineage Cells Results in Increased Bone Mass in Mice by Inhibiting Osteoclastic Bone Resorption.

Authors:  Nan Su; Xiaogang Li; Yubin Tang; Jing Yang; Xuan Wen; Jingyuan Guo; Junzhou Tang; Xiaolan Du; Lin Chen
Journal:  J Bone Miner Res       Date:  2016-04-13       Impact factor: 6.741

9.  Neutral endopeptidase-resistant C-type natriuretic peptide variant represents a new therapeutic approach for treatment of fibroblast growth factor receptor 3-related dwarfism.

Authors:  Daniel J Wendt; Melita Dvorak-Ewell; Sherry Bullens; Florence Lorget; Sean M Bell; Jeff Peng; Sianna Castillo; Mika Aoyagi-Scharber; Charles A O'Neill; Pavel Krejci; William R Wilcox; David L Rimoin; Stuart Bunting
Journal:  J Pharmacol Exp Ther       Date:  2015-02-03       Impact factor: 4.030

10.  C-type natriuretic peptide regulates endochondral bone growth through p38 MAP kinase-dependent and -independent pathways.

Authors:  Hanga Agoston; Sameena Khan; Claudine G James; J Ryan Gillespie; Rosa Serra; Lee-Anne Stanton; Frank Beier
Journal:  BMC Dev Biol       Date:  2007-03-20       Impact factor: 1.978

View more
  67 in total

Review 1.  The genetic basis of disease.

Authors:  Maria Jackson; Leah Marks; Gerhard H W May; Joanna B Wilson
Journal:  Essays Biochem       Date:  2018-12-02       Impact factor: 8.000

Review 2.  Transcriptional network systems in cartilage development and disease.

Authors:  Riko Nishimura; Kenji Hata; Eriko Nakamura; Tomohiko Murakami; Yoshifumi Takahata
Journal:  Histochem Cell Biol       Date:  2018-01-08       Impact factor: 4.304

3.  Osteocyte Death and Bone Overgrowth in Mice Lacking Fibroblast Growth Factor Receptors 1 and 2 in Mature Osteoblasts and Osteocytes.

Authors:  Jennifer McKenzie; Craig Smith; Kannan Karuppaiah; Joshua Langberg; Matthew J Silva; David M Ornitz
Journal:  J Bone Miner Res       Date:  2019-06-17       Impact factor: 6.741

Review 4.  Growth plate skeletal stem cells and their transition from cartilage to bone.

Authors:  Yuki Matsushita; Wanida Ono; Noriaki Ono
Journal:  Bone       Date:  2020-04-07       Impact factor: 4.398

Review 5.  A framework for the radiologic diagnosis of skeletal dysplasias and syndromes as revealed by molecular genetics.

Authors:  Jerry R Dwek
Journal:  Pediatr Radiol       Date:  2019-11-04

Review 6.  Diagnosis, Genetics, and Therapy of Short Stature in Children: A Growth Hormone Research Society International Perspective.

Authors:  Paulo F Collett-Solberg; Geoffrey Ambler; Philippe F Backeljauw; Martin Bidlingmaier; Beverly M K Biller; Margaret C S Boguszewski; Pik To Cheung; Catherine Seut Yhoke Choong; Laurie E Cohen; Pinchas Cohen; Andrew Dauber; Cheri L Deal; Chunxiu Gong; Yukihiro Hasegawa; Andrew R Hoffman; Paul L Hofman; Reiko Horikawa; Alexander A L Jorge; Anders Juul; Peter Kamenický; Vaman Khadilkar; John J Kopchick; Berit Kriström; Maria de Lurdes A Lopes; Xiaoping Luo; Bradley S Miller; Madhusmita Misra; Irene Netchine; Sally Radovick; Michael B Ranke; Alan D Rogol; Ron G Rosenfeld; Paul Saenger; Jan M Wit; Joachim Woelfle
Journal:  Horm Res Paediatr       Date:  2019-09-12       Impact factor: 2.852

7.  Small Peptide Modulation of Fibroblast Growth Factor Receptor 3-Dependent Postnatal Lymphangiogenesis.

Authors:  David P Perrault; Gene K Lee; Sun Young Park; Sunju Lee; Dongwon Choi; Eunson Jung; Young Jin Seong; Eun Kyung Park; Cynthia Sung; Roy Yu; Antoun Bouz; Austin Pourmoussa; Soo Jung Kim; Young-Kwon Hong; Alex K Wong
Journal:  Lymphat Res Biol       Date:  2019-01-16       Impact factor: 2.589

Review 8.  Soluble Factors on Stage to Direct Mesenchymal Stem Cells Fate.

Authors:  Cristina Sobacchi; Eleonora Palagano; Anna Villa; Ciro Menale
Journal:  Front Bioeng Biotechnol       Date:  2017-05-17

9.  Optimizing CRISPR/Cas9 technology for precise correction of the Fgfr3-G374R mutation in achondroplasia in mice.

Authors:  Kai Miao; Xin Zhang; Sek Man Su; Jianming Zeng; Zebin Huang; Un In Chan; Xiaoling Xu; Chu-Xia Deng
Journal:  J Biol Chem       Date:  2018-11-28       Impact factor: 5.157

10.  Dephosphorylation is the mechanism of fibroblast growth factor inhibition of guanylyl cyclase-B.

Authors:  Jerid W Robinson; Jeremy R Egbert; Julia Davydova; Hannes Schmidt; Laurinda A Jaffe; Lincoln R Potter
Journal:  Cell Signal       Date:  2017-09-28       Impact factor: 4.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.